Early immunotherapy for nerve damage linked to anti-Hu antibodies
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a combination of three immune-suppressing drugs (IVIg, cyclophosphamide, and methylprednisolone) given early can improve balance and sensation in people with a rare nerve condition caused by anti-Hu antibodies. The goal is to stop or slow the nerve damage before it gets worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with a sensory nerve problem (sensory neuronopathy) that affects your balance or walking
- Your blood or spinal fluid tests positive for anti-Hu antibodies
- Your nerve symptoms started less than 3 months ago
- You are able to visit the clinic and have a caregiver or support, but you can walk with some help (modified Rankin score 2 or 3)
- You have not had more than 2 courses of IVIg in the last 3 months or other immune treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if IVIG (intravenous immunoglobulin, a treatment that helps the immune system) can reduce pain in people with small fiber nerve damage or sensory neuronopathy. You may qualify if you have had moderate to severe nerve pain for at least 4 weeks and other conditions have been ruled out.
This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.
This study looks at a treatment made from immune proteins (immunoglobulin M) to treat neuropathy caused by anti-MAG antibodies. It may help improve nerve symptoms in people with this specific type of nerve condition.
This early-stage trial tests a new CAR-T cell therapy called HY001N for people with hard-to-treat neurological autoimmune diseases like NMOSD, myasthenia gravis, MS, and others. It aims to see if targeting B cells can help when standard treatments have failed.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Hear when a new Paraneoplastic Sensory Neuronopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.